Inhibitor Therapeutics (OTCMKTS:INTI) Posts Earnings Results

Inhibitor Therapeutics (OTCMKTS:INTI) issued its earnings results on Friday. The company reported ($0.01) earnings per share for the quarter, Zacks reports.

Inhibitor Therapeutics Stock Performance

INTI stock traded up $0.00 during midday trading on Friday, reaching $0.06. 147,145 shares of the company were exchanged, compared to its average volume of 40,416. The company has a market cap of $10.34 million, a price-to-earnings ratio of -6.00 and a beta of -0.55. Inhibitor Therapeutics has a 1-year low of $0.04 and a 1-year high of $0.14. The stock’s 50-day simple moving average is $0.06 and its 200 day simple moving average is $0.07.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.